StonvexLoading…
StonvexStonvexStonvexCore line items from ACM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Annual 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $7.63B | $3.83B | $16.14B | $11.96B |
Operating Income | $469.80M | $222.04M | $1.03B | $789.15M |
Net Income | $254.38M | $74.52M | $561.77M | $441.40M |
EPS (Diluted) | $1.95 | $0.56 | $4.21 | $3.31 |
Total Assets | $12.01B | $11.94B | $12.20B | $12.25B |
Total Liabilities | $9.53B | $9.49B | $9.50B | $9.55B |
Cash & Equivalents | $1.03B | $1.25B | $1.59B | $1.79B |
Free Cash Flow OCF − CapEx | $14.47M | $41.90M | $684.93M | $550.83M |
Shares Outstanding | 128.20M | 129.29M | 131.78M | 132.32M |